Skip to content

Inogen INGN EBITDA margin

EBITDA margin at other companies

ResMed logo
ResMedRMD
38.2%+2.5pp
AdaptHealth logo
AdaptHealthAHCO
12.7%-5.9pp
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
18.5%-0.9pp
Pulmonx Corporation logo
Pulmonx CorporationLUNG
-57.7%-5.5pp
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
11.3%+1.9pp
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
-2.9%-1.3pp

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Calculated from Inogen’s reported figures.

Based on trailing twelve months.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's EBITDA margin?
Inogen (INGN) reported EBITDA margin of -3.3% in Q1 2026.
How has Inogen's EBITDA margin changed year-over-year?
Inogen's EBITDA margin increased by 14.1% year-over-year, from -3.8% to -3.3%.
What is the long-term trend for Inogen's EBITDA margin?
Over 4 years (2020 to 2025), Inogen's EBITDA margin has grown at a 6.5% compound annual growth rate (CAGR), from 2.1% to -2.7%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.